A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
establish additional authorities of the Food and Drug 
Administration regarding the conduct of pediatric inves-
tigations of molecularly targeted drugs to treat cancer, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Give Kids a Chance 
4
Act’’. 
5
17:05 Oct 28, 2021
H5416
2 
•HR 5416 IH
SEC. 2. RESEARCH INTO PEDIATRIC USES OF DRUGS; ADDI-
1
TIONAL AUTHORITIES OF FOOD AND DRUG 
2
ADMINISTRATION 
REGARDING 
MOLECU-
3
LARLY TARGETED CANCER DRUGS. 
4
(a) IN GENERAL.— 
5
(1) AUTHORITY REGARDING INVESTIGATION OF 
6
COMBINATION
OF
ACTIVE
INGREDIENTS.—Section 
7
505B(a)(3) of the Federal Food, Drug, and Cos-
8
metic Act (21 U.S.C. 355c(a)(3)) is amended— 
9
(A) by redesignating subparagraphs (B) 
10
and (C) as subparagraphs (C) and (D), respec-
11
tively; and 
12
(B) by striking subparagraph (A) and in-
13
serting the following: 
14
‘‘(A) IN GENERAL.—For purposes of para-
15
graph (1)(B), the investigation described in this 
16
paragraph is (as determined by the Secretary) 
17
a molecularly targeted pediatric cancer inves-
18
tigation of— 
19
‘‘(i) the drug or biological product for 
20
which the application referred to in such 
21
paragraph is submitted; or 
22
‘‘(ii) the active ingredient or ingredi-
23
ents of such drug or biological product in 
24
combination with— 
25
17:05 Oct 28, 2021
H5416
3 
•HR 5416 IH
‘‘(I) an active ingredient of a 
1
drug or biological product for which 
2
there is in effect an exemption for in-
3
vestigational use under section 505(i) 
4
that was submitted by the person sub-
5
mitting the application referred to in 
6
paragraph (1)(B); or 
7
‘‘(II) an active ingredient of a 
8
drug for which an approval under sec-
9
tion 505 is in effect, or an active in-
10
gredient of a biological product for 
11
which an approval under section 351 
12
of the Public Health Service Act is in 
13
effect. 
14
‘‘(B) ADDITIONAL REQUIREMENTS.— 
15
‘‘(i) DESIGN
OF
INVESTIGATION.—A 
16
molecularly targeted pediatric cancer inves-
17
tigation referred to in subparagraph (A) 
18
shall be designed to yield clinically mean-
19
ingful pediatric study data, gathered using 
20
appropriate formulations for each age 
21
group for which the study is required, re-
22
garding dosing, safety, and preliminary ef-
23
ficacy. 
24
17:05 Oct 28, 2021
H5416
4 
•HR 5416 IH
‘‘(ii) PURPOSE OF INVESTIGATION.— 
1
The purpose of a molecularly targeted pe-
2
diatric cancer investigation referred to in 
3
subparagraph (A) shall be— 
4
‘‘(I) in the case of such an inves-
5
tigation conducted with respect to a 
6
drug or biological product referred to 
7
in clause (i) of such subparagraph, to 
8
inform potential pediatric labeling of 
9
the drug or biological product in-
10
volved; and 
11
‘‘(II) in the case of such an in-
12
vestigation conducted with respect to 
13
a combination of active ingredients 
14
described to in clause (ii) of such sub-
15
paragraph, to assist in determining 
16
the relevance of its molecular target 
17
to the growth or progression of a pe-
18
diatric cancer. 
19
‘‘(iii) PRECLINICAL
DATA.—The re-
20
ports on an investigation required in para-
21
graph (1)(B) shall include the results of all 
22
preclinical studies on which the decision to 
23
conduct such investigation was based. 
24
17:05 Oct 28, 2021
H5416
5 
•HR 5416 IH
‘‘(iv) RULE
OF
CONSTRUCTION
RE-
1
GARDING
INACTIVE
INGREDIENTS.—With 
2
respect to a combination of active ingredi-
3
ents referred to in subparagraph (A)(ii), 
4
such subparagraph may not be construed 
5
as addressing the use of inactive ingredi-
6
ents with such combination. For purposes 
7
of such subparagraph, the Secretary may 
8
establish such requirements with respect to 
9
inactive ingredients as the Secretary deter-
10
mines to be appropriate.’’. 
11
(2) CLARIFYING
APPLICABILITY
OF
CERTAIN 
12
PROVISIONS.—Section 505B(a)(3) of the Federal 
13
Food, 
Drug, 
and 
Cosmetic 
Act 
(21 
U.S.C. 
14
355c(a)(3)), as amended by paragraph (1), is 
15
amended by adding at the end the following: 
16
‘‘(E) INTERNAL COMMITTEE REVIEW; LA-
17
BELING CHANGES; DISSEMINATION OF INFOR-
18
MATION; ADVERSE EVENTS; SCOPE OF AUTHOR-
19
ITY.—Subsections (f) through (j) shall apply 
20
with respect to investigations described in this 
21
paragraph to the same extent and in the same 
22
manner as such subsections apply with respect 
23
to the assessments required under paragraph 
24
(1)(A), except that subsection (g) does not 
25
17:05 Oct 28, 2021
H5416
6 
•HR 5416 IH
apply with respect to an investigation referred 
1
to in subparagraph (A)(ii).’’. 
2
(3) 
CONFORMING
AMENDMENTS.—Section 
3
505B(a) of the Federal Food, Drug, and Cosmetic 
4
Act (21 U.S.C. 355c(a)) is amended— 
5
(A) in paragraph (3)(C), as redesignated 
6
by paragraph (1)(A) of this subsection, by 
7
striking ‘‘investigations described in this para-
8
graph’’ and inserting ‘‘investigations referred to 
9
in subparagraph (A)(i)’’; 
10
(B) in paragraph (3)(D), as redesignated 
11
by paragraph (1)(A) of this subsection, by 
12
striking ‘‘the assessments under paragraph 
13
(2)(B)’’ and inserting ‘‘the assessments re-
14
quired under paragraph (1)(A)’’; and 
15
(C) in paragraph (5)(D), by inserting be-
16
fore the period at the end the following: ‘‘, ex-
17
cept this subparagraph is not applicable to a 
18
drug or biological product that is the subject of 
19
an investigation referred to in paragraph 
20
(3)(A)(ii)’’. 
21
(b) AUTHORITY REGARDING PRECLINICAL STUD-
22
IES.—Section 505B(a)(1) of the Federal Food, Drug, and 
23
Cosmetic Act (21 U.S.C. 355c(a)(1)), as amended by sub-
24
17:05 Oct 28, 2021
H5416
7 
•HR 5416 IH
section (b)(1), is further amended by adding at the end 
1
the following: 
2
‘‘(D) 
PRECLINICAL
STUDIES
GEN-
3
ERALLY.— 
4
‘‘(i) IN GENERAL.—With respect to an 
5
application for an exemption for investiga-
6
tional use under section 505(i) for a drug 
7
or biological product that is intended for 
8
the treatment of an adult cancer, the Sec-
9
retary may require, as a condition of per-
10
mitting the exemption to go into effect, 
11
that the sponsor involved enter into an 
12
agreement with the Secretary to conduct 
13
not more than two preclinical studies of 
14
the drug or biological product in order to 
15
assist in determining the relevance of its 
16
molecular target to the growth or progres-
17
sion of a pediatric cancer. 
18
‘‘(ii) TIMEFRAME
FOR
PRECLINICAL 
19
STUDIES.—With respect to the drug or bi-
20
ological product involved, an agreement 
21
under clause (i) for a preclinical study 
22
shall specify the date by which an initial 
23
plan for the study will be submitted to the 
24
Secretary. The results of the preclinical 
25
17:05 Oct 28, 2021
H5416
8 
•HR 5416 IH
study shall be submitted to the Secretary 
1
in accordance with a timeframe to which 
2
the Secretary and the sponsor involved 
3
have agreed.’’. 
4
(c) APPLICABILITY.—The amendments made by this 
5
section apply with respect to any application under section 
6
505(i) of the Federal Food, Drug, and Cosmetic Act (21 
7
U.S.C. 355(i)), any application under section 505 of such 
8
Act (21 U.S.C. 355), and any application under section 
9
351(a) of the Public Health Service Act (42 U.S.C. 262), 
10
that is submitted on or after the expiration of the 3-year 
11
period beginning on the date of the enactment of this Act. 
12
Æ 
17:05 Oct 28, 2021
H5416
